Childress Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Childress Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$272K	Sell	608 -122	-17%	-$56.9K	0.05%	280
2025 Q4	$331K	Buy	730 +22	+3%	+$9.48K	0.05%	259
2025 Q3	$277K	Sell	708 -52	-7%	-$21.7K	0.05%	236
2025 Q2	$339K	Sell	760 -40	-5%	-$18.4K	0.09%	169
2025 Q1	$388K	Sell	800 -4	-0.5%	-$1.86K	0.11%	130
2024 Q4	$324K	Buy	804 +35	+5%	+$16.2K	0.09%	143
2024 Q3	$358K	Buy	769 +16	+2%	+$7.69K	0.1%	146
2024 Q2	$353K	Sell	753 -47	-6%	-$20.4K	0.1%	138
2024 Q1	$334K	Sell	800 -69	-8%	-$29.2K	0.1%	135
2023 Q4	$354K	Buy	869 +36	+4%	+$13.3K	0.11%	120
2023 Q3	$290K	Buy	+833	New	+$291K	0.09%	130
2023 Q1	–	Sell	-800	Closed	-$231K	–	174
2022 Q4	$231K	Buy	800 +13	+2%	+$3.96K	0.08%	159
2022 Q3	$233K	Hold	787	–	–	0.09%	147
2022 Q2	$222K	Buy	+787	New	+$211K	0.09%	153
2021 Q1	–	Sell	-315	Closed	-$74K	–	929
2020 Q4	$74K	Buy	+315	New	+$72.3K	0.04%	180

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Childress Capital Advisors's VRTX Position: Q1 2026 in Review

Childress Capital Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 17% in Q1 2026, selling an estimated $56.9K and leaving 608 shares worth $272K. The position accounts for 0.05% of the portfolio, ranked #280.

Childress Capital Advisors first reported a position in VRTX in Q4 2020 and has held it in 15 quarters since. The position peaked at $388K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Childress Capital Advisors held 608 shares of Vertex Pharmaceuticals worth $272K as of Q1 2026.
Childress Capital Advisors sold 122 Vertex Pharmaceuticals shares in Q1 2026, an estimated $56.9K.
Vertex Pharmaceuticals made up 0.05% of Childress Capital Advisors's portfolio in Q1 2026, its #280 holding.
Childress Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 15 quarters since.
Childress Capital Advisors's Vertex Pharmaceuticals position peaked at $388K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Childress Capital Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.